FDA Pulls Approval on 72 Discontinued Generic Drug Applications
Published Date: 9/24/2025
Notice
Summary
The FDA is officially pulling the plug on 72 drug approvals because the companies said they stopped selling those medicines. This means those drugs won’t be available anymore, but no one’s losing money or access unexpectedly since the companies chose to stop marketing them. If you’re involved with these drugs, now’s the time to update your records and plans!
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
72 Generic Drug Approvals Withdrawn
The FDA is withdrawing approval of 72 abbreviated new drug applications (ANDAs). The companies told the FDA the products were no longer marketed and asked for the approvals to be withdrawn, so those medicines will no longer be available.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20663, Agency Information Collection Activities; Proposed Collection; Comment Request; Channels of Trade Policy for Commodities With Residues of Pesticide Chemicals, for Which Tolerances Have Been Revoked, Suspended, or Modified by the Environmental Protection Agency Pursuant to Dietary Risk Considerations
The FDA wants your thoughts on how they collect info about food products that might have tiny amounts of banned or changed pesticides. This affects farmers, food sellers, and anyone handling these foods, making sure safety rules keep up with new pesticide limits. You’ve got until December 7, 2026, to share your views—no cost, just your voice!
Previous / Next Documents
Previous: 2025-18452, Self-Regulatory Organizations; Cboe BZX Exchange, Inc.; Notice of Filing and Immediate Effectiveness of a Proposed Rule Change To Establish Certain Market Data Products
Cboe BZX Exchange is launching new market data products to give traders better info on complex options orders. This change affects anyone using BZX’s trading data and starts right away, with some new fees for accessing these data feeds. It’s a smart move to keep traders in the know and the market running smoothly.
Next: 2025-18456, Notice of Determinations; Additional Culturally Significant Object Being Imported for Exhibition-Determinations: “Painted Worlds: Color and Culture in Mesoamerican Art” Exhibition
A new culturally important Mesoamerican art piece is joining the “Painted Worlds: Color and Culture in Mesoamerican Art” exhibition at the Nelson-Atkins Museum in Kansas City. This means visitors get to see even more amazing art, and the display is officially recognized as valuable for the nation. The object will be shown temporarily, with no extra costs to the public.